SCHEMBL312700

SCHEMBL312700

O=c1cc(-c2ccc(O)c(O)c2)oc2ncncc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLH Q9Y253 5/20 0.53
ALOX5 P09917 5/20 0.53
TERT O14746 4/20 0.53
TNKS O95271 3/20 0.53
PARP1 P09874 3/20 0.53
TNKS2 Q9H2K2 3/20 0.53
KDM4E B2RXH2 3/20 0.53
CYP3A4 P08684 3/20 0.53
MAPT P10636 3/20 0.53
ALOX15 P16050 3/20 0.53
HSD17B10 Q99714 3/20 0.53
IP6K2 Q9UHH9 3/20 0.53
MAPK1 P28482 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
FTO Q9C0B1 2/20 0.53
BRD4 O60885 1/20 0.53
ST6GAL1 P15907 1/20 0.53
DHODH Q02127 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL312039 0.86 CYP3A4 (0.52) POLHTERTTNKSPARP1TNKS2
SCHEMBL312399 0.80 KDM4E (0.62) POLHALOX5TERTTNKSPARP1
SCHEMBL312857 0.78 POLH (0.53) POLHALOX5TERTTNKSPARP1
SCHEMBL311738 0.78 HPGD (0.53) POLHALOX5TNKSPARP1TNKS2
SCHEMBL311986 0.77 POLH (0.66) POLHALOX5TERTTNKSPARP1
SCHEMBL311705 0.74 POLH (0.66) POLHALOX5TERTTNKSPARP1
SCHEMBL312234 0.73 POLH (0.50) POLHALOX5TERTTNKSPARP1
SCHEMBL2218499 0.72 POLH (0.75) POLHALOX5TERTTNKSPARP1
SCHEMBL312751 0.71 MAPT (0.59) POLHALOX5TERTTNKSPARP1
SCHEMBL35318 0.70 TERT (1.00) POLHALOX5TERTTNKSPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
EP-1838296-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2007-10-03 EP disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045096-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 POLH 4318/4885ALOX5 986/4885TERT 3484/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 POLH 4318/4885ALOX5 986/4885TERT 3484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.